Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial

被引：0
|
作者：
Ma, Liya [1 ]
Yang, Wenli [1 ]
Zhou, Xinping [1 ]
Ye, Li [1 ]
Xu, Gaixiang [1 ]
Hu, Chao [1 ]
Luo, Yingwan [1 ]
Yang, Chunmei [1 ]
Ge, Zheng [2 ]
Tong, Hongyan [3 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China
[2] Southeast Univ, Zhongda Hosp, Nanjing, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-183101
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Anlotinib plus chemoradiotherapy in the treatment for FIGO stage IB3 and IIB-IVA cervical cancer: A prospective single-arm, single-center, exploratory phase II trial
    Secord, Angeles Alvarez
    Barroilhet, Lisa
    Gupta, Sunil
    Oosman, Sonia
    Tewari, Devansu
    Barlin, Joyce
    Provencher, Diane
    Gold, Michael
    Breed, Christopher
    Edraki, Babak
    Brooks, Rebecca
    Modesitt, Susan
    Braly, Patrica
    Jada, Srinivasa
    Schorge, John
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S157 - S157
  • [22] Anlotinib in patients with recurrent platinum-resistant or platinum-refractory ovarian carcinoma: A prospective, single-center, single-arm, phase II clinical trial
    Wang, Huaying
    Shan, Boer
    Tian, Wenjuan
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S23 - S23
  • [23] Postoperative adalimumab maintenance therapy for Japanese patients with Crohn’s disease: a single-center, single-arm phase II trial (CCOG-1107 study)
    Takahiro Asada
    Goro Nakayama
    Chie Tanaka
    Daisuke Kobayashi
    Kazuhiro Ezaka
    Norifumi Hattori
    Mitsuro Kanda
    Suguru Yamada
    Masahiko Koike
    Yasuhiro Kodera
    Surgery Today, 2018, 48 : 609 - 617
  • [24] Postoperative adalimumab maintenance therapy for Japanese patients with Crohn's disease: a single-center, single-arm phase II trial (CCOG-1107 study)
    Asada, Takahiro
    Nakayama, Goro
    Tanaka, Chie
    Kobayashi, Daisuke
    Ezaka, Kazuhiro
    Hattori, Norifumi
    Kanda, Mitsuro
    Yamada, Suguru
    Koike, Masahiko
    Kodera, Yasuhiro
    SURGERY TODAY, 2018, 48 (06) : 609 - 617
  • [25] Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
    Ravandi, Farhad
    Assi, Rita
    Daver, Naval
    Benton, Christopher B.
    Kadia, Tapan
    Thompson, Philip A.
    Borthakur, Gautam
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina
    Takahashi, Koichi
    Kornblau, Steven
    DiNardo, Courtney D.
    Estrov, Zeev
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James
    Sharma, Padmanee
    Pierce, Sherry
    Pike, Allison
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    LANCET HAEMATOLOGY, 2019, 6 (09): : E480 - E488
  • [26] High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
    Li, Jun
    Huang, Yanqing
    Hou, Yue
    Gu, Yan
    Song, Chunhua
    Ge, Zheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): the open-label, single-arm, single-center, phase 2, CaboPen trial
    Necchi, A.
    Mariani, L.
    Colecchia, M.
    Giannatempo, P.
    Raggi, D.
    Calareso, G.
    Nicolai, N.
    Catanzaro, M.
    Torelli, T.
    Perrone, F.
    Salvioni, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
    O'Donnell, Elizabeth
    Mo, Clifton
    Yee, Andrew J.
    Nadeem, Omar
    Laubach, Jacob
    Rosenblatt, Jacalyn
    Munshi, Nikhil
    Midha, Shonali
    Cirstea, Diana
    Chrysafi, Pavlina
    Horick, Nora
    Richardson, Paul G.
    Raje, Noopur
    LANCET HAEMATOLOGY, 2024, 11 (06): : e415 - e424
  • [29] An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
    Xie, Y.
    Mi, L.
    Zheng, W.
    Ping, L.
    Lin, N.
    Tu, M.
    Zhang, C.
    Ying, Z.
    Liu, W.
    Deng, L.
    Wu, M.
    Wang, X.
    Zhu, J.
    Song, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S652 - S652
  • [30] Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) - protocol for a multi-center, single-arm phase IIa trial
    Frye, Bjoern C.
    Rump, Ina Caroline
    Uhlmann, Annette
    Schubach, Fabian
    Ihorst, Gabriele
    Grimbacher, Bodo
    Zissel, Gernot
    Quernheim, Joachim Mueller
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 19
12345